Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (571-580 of 761) with videos related to

Pageof 77
Sort By:
Expert Review of Cardiovascular Therapy|August 8, 2025
Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directionsVincenzo De Sio, Felice Gragnano, Arturo Cesaro, et al.
Circulation|April 20, 2011
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue, Deepak L Bhatt, Stephen D Wiviott, et al.
Journal of the American Heart Association|August 27, 2015
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical TrialPierluigi Tricoci, Denise M D'Andrea, Paul A Gurbel, et al.
Journal of the American Heart Association|May 27, 2022
Cangrelor Use Patterns and Transition to Oral P2Y<sub>12</sub> Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO RegistryJennifer A Rymer, Deepak L Bhatt, Dominick J Angiolillo, et al.
Journal of Cardiovascular Translational Research|January 8, 2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic studyFabiana Rollini, Francesco Franchi, Jung Rae Cho, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 4, 2024
One-month DAPT with ticagrelor and aspirin for patients undergoing coronary artery bypass grafting: rationale and design of the randomised, multicentre, double-blind, placebo-controlled ODIN trialSigrid Sandner, Mario Gaudino, Bjorn Redfors, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 27, 2023
External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysisAndrea Raffaele Munafò, Claudio Montalto, Marco Franzino, et al.
European Heart Journal|December 17, 2021
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trialsMattia Galli, Stefano Benenati, Francesco Franchi, et al.
International Journal of Cardiology|May 17, 2021
Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous interventionDeepak L Bhatt, Juan Carlos Kaski, Sean Delaney, et al.
Circulation|January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trialShaun G Goodman, Robert Clare, Karen S Pieper, et al.
Pageof 77

Showing results (571-580 of 761) with videos related to

Sort By:
Pageof 77
Expert Review of Cardiovascular Therapy|August 8, 2025
Cangrelor in percutaneous coronary interventions: advances in evidence, clinical applications, and future directionsVincenzo De Sio, Felice Gragnano, Arturo Cesaro, et al.
Circulation|April 20, 2011
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue, Deepak L Bhatt, Stephen D Wiviott, et al.
Journal of the American Heart Association|August 27, 2015
Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical TrialPierluigi Tricoci, Denise M D'Andrea, Paul A Gurbel, et al.
Journal of the American Heart Association|May 27, 2022
Cangrelor Use Patterns and Transition to Oral P2Y<sub>12</sub> Inhibitors Among Patients With Myocardial Infarction: Initial Results From the CAMEO RegistryJennifer A Rymer, Deepak L Bhatt, Dominick J Angiolillo, et al.
Journal of Cardiovascular Translational Research|January 8, 2014
Cigarette smoking and antiplatelet effects of aspirin monotherapy versus clopidogrel monotherapy in patients with atherosclerotic disease: results of a prospective pharmacodynamic studyFabiana Rollini, Francesco Franchi, Jung Rae Cho, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|March 4, 2024
One-month DAPT with ticagrelor and aspirin for patients undergoing coronary artery bypass grafting: rationale and design of the randomised, multicentre, double-blind, placebo-controlled ODIN trialSigrid Sandner, Mario Gaudino, Bjorn Redfors, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 27, 2023
External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysisAndrea Raffaele Munafò, Claudio Montalto, Marco Franzino, et al.
European Heart Journal|December 17, 2021
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trialsMattia Galli, Stefano Benenati, Francesco Franchi, et al.
International Journal of Cardiology|May 17, 2021
Results of an international crowdsourcing survey on the treatment of non-ST segment elevation ACS patients at high-bleeding risk undergoing percutaneous interventionDeepak L Bhatt, Juan Carlos Kaski, Sean Delaney, et al.
Circulation|January 21, 2012
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trialShaun G Goodman, Robert Clare, Karen S Pieper, et al.
Pageof 77